Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACVDL in Newly Diagnosed Multiple Myeloma
NCT01481194Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Nov 2011
- Primary completion
- May 2014
- Modality
- Modified Peptides, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, cyclophosphamide, bortezomib, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Vejle Hospital. Started Nov 2011; status: completed.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidebortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01481194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01481194.